Welcome to our dedicated page for GlycoMimetics news (Ticker: GLYC), a resource for investors and traders seeking the latest updates and insights on GlycoMimetics stock.
GlycoMimetics, Inc. (GLYC) is a clinical-stage biotechnology company dedicated to developing transformative therapies for serious diseases like sickle cell disease, cancer, and other conditions with high unmet medical needs. Founded in 2003, the company leverages its proprietary glycobiology technology to create novel glycomimetic drugs. These drugs are designed to mimic the structure of carbohydrates that play critical roles in various biological processes, potentially offering new avenues of treatment for complex diseases.
GlycoMimetics focuses on areas where carbohydrate biology is crucial, particularly in inflammation, cancer, and infection. The company's robust and diversified product pipeline includes multiple clinical candidates currently in various stages of development. These candidates aim to inhibit disease-related carbohydrate functions, thereby providing hope for patients who currently have limited treatment options.
The company's mission is to advance its research, clinical candidates, and ultimately deliver breakthrough treatments to improve patients' lives. GlycoMimetics is publicly traded on the NASDAQ under the symbol GLYC, reflecting its ongoing commitment to transparency and growth. Recent achievements and current projects highlight the company's commitment to innovation and patient care. GlycoMimetics continues to build strategic partnerships to enhance its research and development efforts, further solidifying its position as a leader in biotechnology.
By using expertise in carbohydrate chemistry and a deep understanding of carbohydrate biology, GlycoMimetics is at the forefront of developing treatments that address significant medical challenges. The company's ongoing projects and collaborations underscore its dedication to making a meaningful impact in the field of biotechnology.
GlycoMimetics, Inc. (Nasdaq: GLYC) announced that CEO Harout Semerjian will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York, NY on September 14, 2022, at 3:00 p.m. ET. An archived recording of the presentation will be accessible for 90 days on GlycoMimetics' website.
The company specializes in developing glycobiology-based therapies for cancers like acute myeloid leukemia (AML), aiming to create transformative treatments through its proprietary platform.
GlycoMimetics, Inc. (NASDAQ: GLYC) has appointed Edwin Rock, M.D., Ph.D., as the new Chief Medical Officer. Dr. Rock brings nearly two decades of biopharmaceutical experience, having previously served as CMO at Partner Therapeutics. He has expertise in clinical development and regulatory functions for therapies aimed at hematologic malignancies. This addition is expected to enhance GlycoMimetics' leadership as it prepares for pivotal Phase 3 data readout of its investigational drug, uproleselan, in acute myeloid leukemia (AML), which has already received Breakthrough Therapy designation from the FDA.
GlycoMimetics (Nasdaq: GLYC) received FDA clearance for its IND application to study GMI-1687 for sickle cell disease. The company is advancing its pivotal Phase 3 trial for uproleselan in relapsed/refractory acute myeloid leukemia (AML), anticipating survival data by mid-2023. As of June 30, 2022, GlycoMimetics reported cash and equivalents of $60.2 million, down from $90.3 million at year-end 2021. R&D expenses decreased to $8.0 million while G&A expenses rose to $5.5 million. A conference call is scheduled for today at 8:30 a.m. ET to discuss these developments.
GlycoMimetics, Inc. (GLYC) announced a conference call on August 3, 2022, at 8:30 a.m. ET, to discuss its second quarter financial results. Investors can participate via a registration link provided in the announcement or access a live webcast through the company’s website. GlycoMimetics is focused on developing glycobiology-based therapies for cancers like acute myeloid leukemia and inflammatory diseases. The company aims to advance its drug candidates to address significant healthcare needs.
GlycoMimetics, Inc. (NASDAQ: GLYC) will participate in the Jefferies 2022 Healthcare Conference on June 8 in New York, NY. CEO Harout Semerjian and CFO Brian Hahn will attend, with a fireside chat hosted by Research Analyst Roger Song, M.D. The chat will be available for 30 days on the GlycoMimetics website starting June 8 at approximately 3:30 p.m. ET. GlycoMimetics is a clinical-stage biotechnology company focused on developing glycobiology-based therapies for cancers and inflammatory diseases, aiming to create transformative treatments.
GlycoMimetics (NASDAQ: GLYC) reported its financial results for Q1 2022, with cash and equivalents at $76.5 million, down from $90.3 million at the end of 2021. The company recorded no revenue for the quarter compared to $1.1 million in Q1 2021. Research and development expenses decreased to $9.6 million, while general and administrative expenses rose to $5.1 million. The company is on track for key events in its clinical trials, including the pivotal Phase 3 trial for uproleselan in relapsed/refractory AML anticipated in mid-2023.
GlycoMimetics, Inc. (Nasdaq: GLYC) will host a conference call and webcast on
GlycoMimetics, Inc. (Nasdaq: GLYC) will participate in the 34th Annual Roth Conference on March 14-15 in Laguna Niguel, California. CEO Harout Semerjian and CFO Brian Hahn will attend, with a fireside chat hosted by Research Analyst Zegbeh Jallah. An archived recording will be available on the GlycoMimetics website starting March 15 at approximately 2:00 p.m. PST. The company focuses on developing glycobiology-based therapies for cancers and inflammatory diseases. For more information, visit www.glycomimetics.com.
GlycoMimetics, Inc. (NASDAQ:GLYC) announced the grant of a stock option award on March 1, 2022, for 100,000 shares to Deepak Tiwari, its new Vice President of Technical Operations. This award, approved by the compensation committee, is a non-qualified stock option granted outside the 2013 Equity Incentive Plan, complying with NASDAQ Listing Rule 5635(c)(4). The options vest 25% on March 1, 2023, with the remainder vesting monthly over three years. The exercise price is set at $1.27 per share, equal to the closing stock price on the grant date.
GlycoMimetics, Inc. (Nasdaq: GLYC) reported its financial results for Q4 and year-end 2021. The company has $90.3 million in cash, down from $137.0 million in 2020. Revenue dropped to $1.2 million from $10.2 million, mainly due to decreased collaboration payments. R&D expenses rose to $12.9 million in Q4 and $47.5 million for the year, driven by increased clinical development costs for uproleselan in AML. The pivotal Phase 3 trial for uproleselan in relapsed/refractory AML has completed enrollment of 388 patients, with top-line data expected after year-end 2022.
FAQ
What is the current stock price of GlycoMimetics (GLYC)?
What is the market cap of GlycoMimetics (GLYC)?
What does GlycoMimetics, Inc. specialize in?
What are glycomimetic drugs?
What is the company's mission?
When was GlycoMimetics founded?
What is the stock symbol for GlycoMimetics?
What diseases is GlycoMimetics targeting with its treatments?
How does GlycoMimetics develop its treatments?
What recent achievements has GlycoMimetics made?
How can I get the latest news about GlycoMimetics?
What is the significance of GlycoMimetics' research?
